ReviewFrontiers in cell and developmental biology2025
Plakophilin 1 in cancer: context-dependent dualism, subcellular dynamics, and therapeutic targeting.
Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plakophilin 1 (PKP1) is a desmosomal protein that plays a dual role in cancer, acting as either an oncogene or a tumor suppressor depending on the context. This review consolidates evidence regarding its mechanistic regulation via crucial signaling pathways, including Wnt/β-catenin, PI3K/AKT, and MAPK and underscores its potential as a clinical biomarker. The function of PKP1 is influenced by its subcellular localization: when membrane-bound, PKP1 stabilizes cell adhesion, whereas in the cytoplasm or nucleus, it facilitates oncogenesis by promoting MYC translation and modulating DNA damage. Phosphorylation events further refine this functional plasticity. Clinically, PKP1 expression is valuable for cancer subtyping and prognosis. This review also addresses unresolved questions concerning its regulation and suggests that future research in these areas could unlock the potential of PKP1 in precision oncology strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.